People on the Move
Spinifex Pharmaceuticals
Spinifex, a pain drug development company based in Stamford, Connecticut and Melbourne, Australia, has appointed Ronald Marcus as Chief Medical Officer. The new CMO will be responsible for developing the company’s lead candidate EMA401 as well as its preclinical pipeline.
EMA401 is a novel angiotensin II type 2 receptor antagonist being developed as for the treatment of chronic pain without CNS side-effects.
Marcus has more than 20 years’ experience in clinical development experience. He joins Spinifex from Bristol-Myers Squibb (BMS), where he has held several senior positions in neuroscience. These include Executive Director, Neuroscience Global Clinical Research, where he led life-cycle management of Ablify (Aripiprazole).
